Teleflex (TFX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 2.4% year-over-year to $764.4 million; adjusted EPS was $3.49, down 4.1% year-over-year, but above expectations due to strong margin performance.

• Margin expansion and adjusted operating income growth achieved, supported by a diversified portfolio and global footprint, with Interventional and Vascular Access offsetting OEM softness.

• Integration of Palette Life Sciences (Barrigel) progressing well, with product momentum and 2024 revenue guidance raised to $73-$75 million.

• $500 million share repurchase authorized, including $200 million accelerated program in Q3; net leverage at 1.7x.

• Clinical updates included positive Titan SGS Stapler study results and first patient enrolled in Barrigel rectal spacer trial.

Financial highlights

• Adjusted gross margin rose to 60.8%, up 140 basis points year-over-year, driven by MSA termination, Palette acquisition, and favorable pricing; GAAP gross margin was 56.3%.

• Adjusted operating margin was 27.3%, up 10 basis points year-over-year; GAAP operating margin was 19.5%.

• Cash flow from operations for the first nine months was $435.6 million, up from $372.4 million year-over-year.

• Net interest expense increased to $18.8 million in Q3, with nine-month interest expense at $64.9 million.

• SG&A expenses rose in Q3 2024, mainly due to prior year contingent consideration benefit and Palette acquisition costs.

Outlook and guidance

• 2024 adjusted constant currency revenue growth guidance revised to 3.5%-4% (from 4.25%-5.25%); GAAP revenue growth expected at 2.9%-3.4%.

• 2024 adjusted EPS guidance raised to $13.90-$14.20; GAAP EPS guidance raised to $6.65-$6.95.

• Gross margin guidance raised to 60.5%-61%; operating margin guidance raised to 26.75%-27%.

• Fourth quarter revenue expected at $809-$824 million, up 4.6%-6.5% year-over-year on adjusted constant currency basis.

• Foreign exchange expected to have a negative 0.15% impact on full-year revenue.